AMPH NASDAQ
Credit Risk of going bust: higher than 70% of companies Debt: 38.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.35 (down 95%), Amphastar Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $688.3M against a stock market value of $1.08B.
Distance to default 3.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $307.3M (short-term plus half of long-term), stock volatility 53.9%; Altman Z 2.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Rancho Cucamonga, CA 91730
US
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| PETERS WILLIAM J | S-Sale | 4,139 | $25.00 | 2026-09-21 |
| Zhou Rong | M-Exempt | 10,000 | $13.35 | 2026-09-16 |
| Zhou Rong | S-Sale | 10,000 | $23.94 | 2026-09-16 |
| Zhou Rong | M-Exempt | 10,000 | $13.35 | 2026-09-16 |
| Zhou Rong | S-Sale | 3,187 | $23.63 | 2026-09-02 |